Download PDF
Semin Liver Dis 2004; 24: 3-8
DOI: 10.1055/s-2004-832922
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

The Natural History of Hepatitis C

Nezam H. Afdhal1
  • 1Medical Director, Liver Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Further Information

Publication History

Publication Date:
02 September 2004 (online)

    Permissions and Reprints

Hepatitis C virus (HCV) is the most common cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) in the United States and infects an estimated 170 million people worldwide. In the United States, overall hepatitis C prevalence is 1.8% and is higher in African Americans and Hispanics than it is in white Americans. The age distribution places 65% of all subjects with anti-HCV antibodies between 30 and 49 years of age. Before serological screening of blood products was initiated, hepatitis C was most commonly transmitted by transfusion of contaminated blood products, but now it is acquired primarily via intravenous drug use. Only 10 to 25% of infected adult patients spontaneously resolve their infection, and the remaining 75% remain persistently viremic and often asymptomatic. Progression of liver disease in 20 to 30% of patients can lead to compensated and eventually decompensated cirrhosis or hepatocellular carcinoma, or both. This article looks briefly at the epidemiology and natural history of hepatitis C.

KEYWORDS

Chronic hepatitis C - natural history

REFERENCES

  • 1 Di Bisceglie A M. Hepatitis C.  Lancet. 1998;  351 351-355
    CrossrefPubMedGoogle Scholar
  • 2 Centers for Disease Control and Prevention (CDC) . Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related disease.  MMWR Morb Mortal Wkly Rep. 1998;  47 1-40
    PubMedGoogle Scholar
  • 3 , Anonymous Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.  J Viral Hepat. 1999;  6 35-47
    CrossrefPubMedGoogle Scholar
  • 4 McQuillan G, Alter M, Moyer L, Lambert S, Margolis H. A population based serologic study of hepatitis C virus infection in the United States. In: Rizzetto M, Purcell RH, Gerin JL, et al Viral Hepatitis and Liver Disease. Turin; Edizioni Minerva Medica 1997: 267-270
    Google Scholar
  • 5 Alter M, Kruszon-Moran D, Nainan O et al.. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.  N Engl J Med. 1999;  341 556-562
    CrossrefPubMedGoogle Scholar
  • 6 Armstrong G L, Alter M J, McQuillan G M, Margolis H S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States.  Hepatology. 2000;  31 777-782
    CrossrefPubMedGoogle Scholar
  • 7 , Anonymous Management of hepatitis C.  NIH Consens Statement. 1997;  15 1-41
    PubMedGoogle Scholar
  • 8 Davis G L, Albright J E, Cook S F, Rosenberg D M. Projecting the future healthcare burden from hepatitis C in the United States.  Hepatology. 1998;  28 390A
    PubMedGoogle Scholar
  • 9 Wong J B, McQuillan G M, McHutchison J G, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States.  Am J Public Health. 2000;  90 1562-1569
    PubMedGoogle Scholar
  • 10 Kim W R, Gross Jr J B, Poterucha J J, Locke III G R, Dickson E R. Outcome of hospital care of liver disease associated with hepatitis C in the United States.  Hepatology. 2001;  33 201-206
    CrossrefPubMedGoogle Scholar
  • 11 Spaulding A, Greene C, Davidson K, Schneidermann M, Rich J. Hepatitis C in state correctional facilities.  Prev Med. 1999;  28 92-100
    CrossrefPubMedGoogle Scholar
  • 12 Vlahov D, Nelson K E, Quinn D C, Kendig N. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland.  Eur J Epidemiol. 1993;  9 566-569
    PubMedGoogle Scholar
  • 13 Austin G E, Jensen B, Leete J et al.. Prevalence of hepatitis C virus seropositivity among hospitalized US veterans.  Am J Med Sci. 2000;  319 353-359
    PubMedGoogle Scholar
  • 14 Cheung R C. Epidemiology of hepatitis C virus infection in American veterans.  Am J Gastroenterol. 2000;  95 740-747
    CrossrefPubMedGoogle Scholar
  • 15 Simmonds P, Holmes E C, Cha T A et al.. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region.  J Gen Virol. 1993;  74 2391-2399
    PubMedGoogle Scholar
  • 16 Honda M, Kaneko S, Sakai A et al.. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease.  Hepatology. 1994;  20 1144-1151
    CrossrefPubMedGoogle Scholar
  • 17 Zein N N, Rakela J, Krawitt E L et al.. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group.  Ann Intern Med. 1996;  125 634-639
    PubMedGoogle Scholar
  • 18 Ferreira-Gonzalez A, Shiffman M L. Diagnostic testing of hepatitis C virus infection.  Semin Liver Dis. 2004;  24(suppl 2) 9-18
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Shakil A O, Conry-Cantilena C, Alter H J et al.. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features.  Ann Intern Med. 1995;  123 330-337
    PubMedGoogle Scholar
  • 20 Seeff L B. Natural history of hepatitis C.  Am J Med. 1999;  107 10S-15S
    PubMedGoogle Scholar
  • 21 Boyer N, Marcellin P. Natural history of hepatitis C and the impact of anti-viral therapy.  Forum (Genova). 2000;  10 4-18
    PubMedGoogle Scholar
  • 22 Jaeckel E, Cornberg M, Wedemeyer H et al.. Treatment of acute hepatitis C with interferon alfa-2b.  N Engl J Med. 2001;  345 1452-1457
    CrossrefPubMedGoogle Scholar
  • 23 Mathurin P, Moussalli J, Cadranel J F et al.. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity.  Hepatology. 1998;  27 868-872
    CrossrefPubMedGoogle Scholar
  • 24 Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.  N Engl J Med. 1999;  340 1228-1233
    CrossrefPubMedGoogle Scholar
  • 25 Asselah T, Martinot M, Cazals Hatem D et al.. Hypervariable region 1 quasispecies in HCV genotypes 1b and 3 infected patients with normal and abnormal ALT levels.  J Virol Hepatol. 2002;  9 29-35
    PubMedGoogle Scholar
  • 26 Alter M J, Margolis H S, Krawczynski K et al.. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.  N Engl J Med. 1992;  327 1899-1905
    CrossrefPubMedGoogle Scholar
  • 27 Diepolder H M, Gerlach J T, Zachoval R et al.. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection.  J Virol. 1997;  71 6011-6019
    PubMedGoogle Scholar
  • 28 Wong D K, Dudley D D, Afdhal N H et al.. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection.  J Immunol. 1998;  160 1479-1488
    PubMedGoogle Scholar
  • 29 Missale G, Bertoni R, Lamonaca V et al.. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.  J Clin Invest. 1996;  98 706-714
    PubMedGoogle Scholar
  • 30 Diepolder H M, Zachoval R, Hoffmann R M et al.. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection.  Lancet. 1995;  346 1006-1007
    CrossrefPubMedGoogle Scholar
  • 31 Hiroishi K, Kita H, Kojima M et al.. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection.  Hepatology. 1997;  25 705-712
    CrossrefPubMedGoogle Scholar
  • 32 Zinkernagel R M. Immunology taught by viruses.  Science. 1996;  271 173-178
    PubMedGoogle Scholar
  • 33 Tong M J, el-Farra N S, Reikes A R, Co R L. Clinical outcomes after transfusion-associated hepatitis C.  N Engl J Med. 1995;  332 1463-1466
    CrossrefPubMedGoogle Scholar
  • 34 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.  Lancet. 1997;  349 825-832
    CrossrefPubMedGoogle Scholar
  • 35 Seeff L B, Hollinger F B, Alter H J et al.. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute Collaborative Study.  Hepatology. 2001;  33 455-463
    CrossrefPubMedGoogle Scholar
  • 36 Shehab T, Orrego M, Lok A. Spectrum of liver disease in hepatitis C patients presenting to primary care clinics.  Gastroenterology. 2001;  120 A369
    PubMedGoogle Scholar
  • 37 Fattovich G, Giustina G, Degos F et al.. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.  Gastroenterology. 1997;  112 463-472
    CrossrefPubMedGoogle Scholar
  • 38 Shiffman M L. Improvement in liver histopathology associated with interferon therapy in patients with chronic hepatitis C.  Viral Hepatol Rev. 1999;  5 27-43
    PubMedGoogle Scholar
  • 39 Mohamed A E, Ven D, Al Karawi M A. Dual infection with hepatitis C and B viruses: clinical and histologic study in Saudi patients.  Hepatogastroenterology. 1997;  44 1404-1406
    PubMedGoogle Scholar
  • 40 Zarski J-P, Bohn B, Bastie A. Characteristics of patients with dual infection by hepatitis B and C viruses.  J Hepatol. 1998;  28 27-33
    CrossrefPubMedGoogle Scholar
  • 41 Sulkowski M S, Mast E E, Seeff L B, Thomas D L. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus.  Clin Infect Dis. 2000;  30(Suppl 1) S77-S84
    CrossrefPubMedGoogle Scholar
  • 42 Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C.  J Hepatol. 2000;  32(Suppl 1) 98-112
    PubMedGoogle Scholar
  • 43 Zylberberg H, Rimaniol A C, Pol S et al.. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity.  J Hepatol. 1999;  30 185-191
    CrossrefPubMedGoogle Scholar
  • 44 Perrella A, Perrella, Conca P, Tarantino G. CD8+/CD38+: immune activity and clinical significance in HCV patients with and without interferon therapy.  Eur Rev Med Pharmacol Sci. 2000;  4 127-131
    PubMedGoogle Scholar
  • 45 Shiffman M L, Stewart C A, Hofmann C M et al.. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy.  J Infect Dis. 2000;  182 1595-1601
    CrossrefPubMedGoogle Scholar
  • 46 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States N Engl.  J Med. 1999;  340 745-750
    CrossrefPubMedGoogle Scholar
  • 47 Godley P A, Sandler R S. Liver cancer. In: Everhart JE Digestive Diseases in the United States: Epidemiology and Impact. Washington, DC; National Institutes of Health 1994: 227-241
    Google Scholar

Nezam H AfdahlM.D. 

Liver Center, Beth Israel Deaconess Medical Center

330 Brookline Avenue

Boston, MA 02215

Email: nafdhal@caregroup.harvard.edu